Relmada Therapeutics, Inc. RLMD Short-term investments sold
Short-term investments sold at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfShortTermInvestments.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s short-term investments sold.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s short-term investments sold?
- Relmada Therapeutics, Inc. (RLMD) reported short-term investments sold of $14.29M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s short-term investments sold changed year-over-year?
- Relmada Therapeutics, Inc.'s short-term investments sold decreased by 9.8% year-over-year, from $15.85M to $14.29M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s short-term investments sold?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s short-term investments sold has grown at a -32.2% compound annual growth rate (CAGR), from $168.86M to $35.69M.
- What does short-term investments sold mean?
- The total cash inflow generated from the sale or maturity of short-term financial instruments. This metric highlights the company's ability to convert liquid assets back into cash to fund operations or other investments.